Efficacy of Adalimumab in Patients With Crohn's Disease and Failure to Infliximab Therapy: A Clinical Series

Revista Espanola de Enfermedades Digestivas - Spain
doi 10.4321/s1130-01082011000600003
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Instituto de Salud Carlos III/BNCS/SciELO Espana

Related search

Efficacy of Infliximab Biosimilars in Patients With Crohn's Disease

The Lancet
Medicine
2017English

Clinical Efficacy of Adalimumab Versus Infliximab and the Factors Associated With Recurrence or Aggravation During Treatment of Anal Fistulas in Crohn's Disease

Intestinal Research
Gastroenterology
2017English

Adalimumab - An Effective and Promising Treatment for Patients With Fistulizing Crohn's Disease: A Case Series

Journal of Medical Case Reports
Medicine
2011English

Infliximab and Adalimumab Drug Levels in Crohn's Disease: Contrasting Associations With Disease Activity and Influencing Factors

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2017English

Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease

New England Journal of Medicine
Medicine
2010English

Efficacy and Safety of Infliximab Versus Adalimumab in the Therapy of Fistulizing Crohn Disease: A Systematic Review and Indirect Comparison

2020English

Combination Therapy With Adalimumab Plus Intensive Granulocyte and Monocyte Adsorptive Apheresis Induced Clinical Remission in a Crohn's Disease Patient With the Loss of Response to Scheduled Adalimumab Maintenance Therapy: A Case Report

Internal Medicine
Internal MedicineMedicine
2012English

Editorial: First Among Equals-Not for Either Infliximab or Adalimumab in Crohn's Disease-Yet

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2018English

Long-Term Safety of Adalimumab in Clinical Trials in Adult Patients With Crohn's Disease or Ulcerative Colitis

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy